Tg Therapeutics (TGTX) Research & Development (2011 - 2026)
Tg Therapeutics (TGTX) posted quarterly Research & Development of $43.5 million for Q1 2026, down 6.13% year-over-year from $46.4 million in Q1 2025, and up 5.65% quarter-over-quarter from $41.2 million in Q4 2025.
Tg Therapeutics (TGTX) Research & Development (2011 - 2026) Analysis & Trends
Tg Therapeutics' Research & Development history runs 16 years deep, the most recent figure standing at $43.5 million for Q1 2026.
- In Q1 2026, Research & Development fell 6.13% year-over-year to $43.5 million; the TTM figure through Mar 2026 stood at $152.0 million (up 45.12% YoY), while the FY2025 annual figure was $160.2 million, up 92.73% from the prior year.
- Research & Development for Q1 2026 stood at $43.5 million, up from $41.2 million in the prior quarter.
- The five-year high for Research & Development was $48.0 million in Q1 2022, with the low at $11.8 million in Q3 2023.
- The 5-year median for Research & Development is $26.9 million (2022), against an average of $27.9 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development plunged 71.54% in 2022, then surged 106.19% in 2024.
- Tg Therapeutics' Research & Development stood at $16.4 million in 2022, then gained by 6.33% to $17.4 million in 2023, then grew by 18.71% to $20.7 million in 2024, then surged by 98.87% to $41.2 million in 2025, then climbed by 5.65% to $43.5 million in 2026.
- Business Quant data shows TGTX's Research & Development at $43.5 million in Q1 2026, $41.2 million in Q4 2025, and $35.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 95.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.34 Mn |
| Mar 31, 2026 | 43.52 Mn |
| Dec 31, 2025 | 41.19 Mn |
| Sep 30, 2025 | 35.54 Mn |
| Jun 30, 2025 | 31.78 Mn |
| Mar 31, 2025 | 46.36 Mn |
| Dec 31, 2024 | 20.71 Mn |
| Sep 30, 2024 | 20.14 Mn |
| Jun 30, 2024 | 17.56 Mn |
| Mar 31, 2024 | 32.72 Mn |
| Dec 31, 2023 | 17.45 Mn |
| Sep 30, 2023 | 11.84 Mn |
| Jun 30, 2023 | 28.12 Mn |
| Mar 31, 2023 | 15.87 Mn |
| Dec 31, 2022 | 16.41 Mn |
| Sep 30, 2022 | 20.80 Mn |
| Jun 30, 2022 | 26.87 Mn |
| Mar 31, 2022 | 48.04 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 47.43 Mn |